Table 1. Suggested readings to accompany WTL assignments and essay prompt about making a decision
about what cancer treatment to recommend to a friend or relative who is a cancer patient. These readings
are more recent. Some are suitable for introductory courses (reviews and opinion articles) and some are
appropriate for more advanced biology students (primary research articles).
Topic Article Citation Article Type
Altieri, D.C. (2008). Surviving, cancer networks and pathway-directed drug
discovery. Nature Reviews Cancer, 8, 61.
Johnston, P.A. & Grandis, J.R. (2011). STAT3 signaling: anticancer strategies
and challenges. Molecular Interventions, 11, 18.
Yap, T.A, Sandhu, S.K., Workman, P. & de Bono, J.S. (2010). Envisioning the
future of early anticancer drug development. Nature Reviews Cancer, 10,
Nass, S.J., Rothenberg, M.L., Pentz, R., Hricak, H., Abernethy, A., Anderson, K.,
et al. (2018). Accelerating anticancer drug development – opportunities
and trade-offs. Nature Reviews Clinical Oncology, 1.
Kolata, G. (2017). A cancer conundrum: too many drug trials, too few
patients. New York Times, August 12.
Grady, D. (2016). In cancer trials, minorities face extra hurdles. New York
Times, December 23.
Mole, B. (2015). Biology may provide just the right chemistry for new
drugs. Science News, July 20.
Liu, F., Li, W., Hua, S., Han, Y., Xu, Z., Wan, D., et al. (2018). Nigericin
exerts anticancer effects on human colorectal cancer by inhibiting
wnt/beta-catenin signaling pathway. Molecular Cancer Therapeutics, 17,
Szakács, G., Paterson, J.K., Ludwig, J.A., Booth-Genthe, C. & Gottesman, M.
M. (2006). Targeting multidrug resistance in cancer. Nature Reviews Drug
Discovery, 5, 219.
Blanco, E., Shen, H. & Ferrari, M. (2015). Principles of nanoparticle design for
overcoming biological barriers to drug delivery. Nature Biotechnology, 33,
Johnson, T.M. (2016). Overcoming multidrug-resistant cancer with smart
nanoparticles. NIH/BIB Science Highlights, August 23.
Felix Spenkuch (2017). No to multi-drug-resistant cancer. Advanced Science
News, February 22.
Robey, R.W., Pluchio, K.M., Hall, M.D., Fojo, A. T., Bates, S.E. & Gottesman, M.
M. (2018). Revisiting the role of ABC transporters in multidrug-resistant
cancer. Nature Reviews Cancer, 18, 452–464.
Lee, W.H., Loo, C.Y., Young, P.M., Traini, D., Mason, R.S. & Rohanizadeh, R.
(2014). Recent advances in curcumin nanoformulation for cancer therapy.
Expert Opinion on Drug Delivery, 11, 1183–1201.
Esser, L., Zhou, F., Pluchino, K.M., Shiloach, J., Ma, J.,Tang, W.K., et al. (2017).
Structures of the multidrug transporter P-glycoprotein reveal asymmetric
ATP binding and the mechanism of polyspecificity. Journal of Biological
Chemistry, 292, 446–461.
Jeyaraj, M., Sathishkumar, G., Sivanandhan, G., MubarakAli, D., Rajesh, M.,
Arun, R., et al. (2013). Biogenic silver nanoparticles for cancer treatment: an
experimental report. Colloids and Surfaces B, 106, 86–92.